Related Experiment Video
Updated: Jul 17, 2026

A Screening Method for Identification of Heterochromatin-Promoting Drugs Using Drosophila
Published on: March 12, 2020
Drug-target identification in Drosophila cells: combining high-throughout RNAi and small-molecule screens
Norbert Perrimon1, Adam Friedman, Bernard Mathey-Prevot
1Department of Genetics, Howard Hughes Medical Institute, Harvard Medical School, Boston, MA 02115, USA. perrimon@receptor.med.harvard.edu
Abstract:
RNA interference (RNAi) and small-molecule approaches are synergistic on multiple levels, from technology and high-throughput screen development to target identification and functional studies. Here, we describe the RNAi screening platform that we have established and made available to the community through the Drosophila RNAi Screening Center at Harvard Medical School. We then illustrate how the combination of RNAi and small-molecule HTS can lead to effective identification of targets in drug discovery.
Related Concept Videos
Experimental RNAi
Genetic Screens
Forward genetic screens
Forward or “classical” genetic screens involve creating random mutations in an organism’s DNA using radiation, mutagens, or insertion of additional bases, which result in visible changes...

